The FDA announces Zantac recalls due to cancer concerns linked to bladder, liver, and stomach cancers found in people taking Zantac, a popular drug used to relieve heartburn.
Zantac Linked to Cancer
Zantac, known as ranitidine in generic form, has been recalled by the U.S. Food and Drug Administration (FDA). Based on FDA laboratory test results, ranitidine contains low levels of a nitrosamine impurity (NDMA), a known human carcinogen. As a result of FDA findings, Zantac has been pulled from store shelves at pharmacies, drug stores, and retail stores across the country.
For years. the FDA has been investigating NDMA found in certain batches of blood pressure and heart failure medicines which prompted federal recalls. In 2019, NDMA was discovered in certain batches of ranitidine drugs, commonly taken to treat heartburn and ulcers. In addition to potentially causing cancer in humans, FDA research shows that overexposure to NDMA can cause vomiting, fever, jaundice, arrhythmia, and nervous system disorders.
Zantac is the most widely used heartburn drug in America. Doctors write more than 15 million prescriptions for the Zantac each year, and countless more patients buy it over the counter. Prescription Zantac is available in oral tablets and capsules, an oral liquid, and an injectable solution, while over-the-counter Zantac is sold mostly in tablets.
The FDA warns that people should not consume more than 96 nanograms of NDMA per day, but lab test results found more than 3,000,000 nanograms in some Zantac tablets. In April 2020, the FDA announced that ranitidine presents a public health risk to consumers and requested that manufacturers of ranitidine products remove all Zantac prescription drugs and over-the-counter drugs from the market.
Zantac Lawsuits on the Rise
Since news of Zantac recalls and links to cancer became public, Zantac cancer attorneys have seen thousands of lawsuits filed against ranitidine manufacturers. People who took Zantac and developed cancer have filed personal injury lawsuits. People who took Zantac and did not become ill have filled class action lawsuits. In both cases, injury claims allege that Zantac manufacturers were aware of potential NDMA cancer-causing risks, but failed to warn the public.
In 2019, the first class action Zantac lawsuit was filed in California against manufacturers Sanofi and Boerhringer Ingelheim. The lawsuit alleges dangerous levels of NDMA in a single Zantac pill that far exceeds the FDA acceptable levels for safe daily intake, resulting in the potential for cancers of the bladder, liver, stomach, pancreas, and colon, as well as internal bleeding, and death.
With a rise in Zantac lawsuits across the country, Sanofi and Boerhringer Ingelheim have recalled all Zantac over-the-counter drugs in the United States and Canada. Major U.S. retailers that sell Zantac including Target, Walgreens, and CVS have removed all Zantac products from shelves until further notice.
In most states, the law allows people who developed cancer after taking Zantac to file a personal injury lawsuit with a Zantac cancer attorney. Injury victims can recover the maximum possible compensation for medical expenses, lost wages and future earnings, pain and suffering, temporary or permanent disability, and other compensable damages, including punitive damages in some cases.
People who have taken Zantac, but show no signs of developing cancer, can file class action lawsuits through a Zantac cancer attorney to recover money spent on Zantac drugs during their course of treatment.